HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by YazicioGlu, L. Articles by Akalin, H. Search for Related Content PubMed PubMed Citation Articles by YazicioGlu, L. Articles by Akalin, H. Related Collections Cardiac - pharmacology

J Thorac Cardiovasc Surg 2001;122:741-745
© 2001 The American Association for Thoracic Surgery

Cardiopulmonary Support and Physiology

Recombinant human erythropoietin administration in cardiac surgery

Levent Yaziciolu, MD, Sadik Eryilmaz, MD, Mustafa irlak, MD, Mustafa Bahadir nan, MD, Atilla Aral, MD, Refik Taöz, MD, Neyyir Tuncay Eren, MD, Bülent Kaya, MD, Hakki Akalin, MD

From the Department of Cardiovascular Surgery, Ankara University Faculty of Medicine Hospital, Ankara, Turkey.

Received for publication Oct 17, 2000. Revisions requested Jan 2, 2001; revisions received Feb 5, 2001. Accepted for publication Feb 20, 2001. Address for reprints: Levent Yaziciolu, Bilkent 2 Park Sitesi G-4 Blok No: 22/32, 06530 Ankara, Turkey (E-mail: hyazici@ domi.com.tr).

Objective: Postoperative anemia and multiple blood transfusions are still important problems in cardiac surgery. During the past few years, there have been some reports indicating that multiple recombinant human erythropoietin infusions starting at least 2 weeks before the operation induced erythropoiesis. We aimed to reduce the risk of adverse reactions of high doses of recombinant human erythropoietin and reduce the period of hospitalization by using it only once, 4 days before the operation.
Methods: Twenty-five patients received recombinant human erythropoietin 4 days before the operation, and 28 patients comprised the control group. All the hematologic parameters of the patients are measured on the day of admission, the day before the operation (fourth day), the first day after the operation, and 1 week later.
Results: In the recombinant human erythropoietin group the mean hemoglobin concentration increased on the morning of the operation (14.5 ± 0.52 g/dL in the recombinant human erythropoietin group and 12.4 ± 0.65 in the control group, P < .05). To maintain hemoglobin levels at greater than 8.5 g/dL, 330 ± 33 mL of homologous transfusion was required in the recombinant human erythropoietin group, whereas 680 ± 75 mL was required in the control group (P < .01).
Conclusion: Recombinant human erythropoietin induces erythropoiesis rapidly, even when it is used with a low single dose just 4 days before the operation. No adverse reactions were seen with this kind of recombinant human erythropoietin treatment.

This article has been cited by other articles:

				S. Price, J. R. Pepper, and S. I. Jaggar Recombinant Human Erythropoietin Use in a Critically Ill Jehovah's Witness After Cardiac Surgery Anesth. Analg., August 1, 2005; 101(2): 325 - 327. [Abstract] [Full Text] [PDF]

				A. Shander, D. Moskowitz, and T. S. Rijhwani The Safety and Efficacy of "Bloodless" Cardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2005; 9(1): 53 - 63. [Abstract] [PDF]

				S. M. Bagshaw and W. A. Ghali Erythropoietin and Transfusions Among Critically Ill Patients JAMA, March 26, 2003; 289(12): 1511 - 1511. [Full Text] [PDF]

				Y. J. Woo and T. J. Gardner Myocardial Revascularization with Cardiopulmonary Bypass Card. Surg. Adult, January 1, 2003; 2(2003): 581 - 607. [Full Text]